Spend on mental health will need to double to bring the proportion of people receiving NHS treatment up from 40 percent to 70 percent, claims a report commissioned by the NHS Confederation. More: Mental health spend must double to raise
read moreThe National Institute for Health and Care Excellence (NICE) has now issued guidance recommending Janssen’s Tremfya as an option for treating plaque psoriasis in adults on the NHS. More: Final NICE nod for Janssen’s Tremfya Source: News
read moreMylan has announced that US regulators are going to reject its generic version of GlaxoSmithKline’s asthma/COPD inhaler Advair Diskus. More: FDA to reject Mylan’s Advair Diskus generic Source: News
read moreViiV Healthcare’s two-drug HIV regimen of Tivicay and Epivir has hit targets in late-stage trials, showing non-inferiority to a three-drug regimen and thus the potential to offer patients an alternative treatment strategy. More: ViiV’s two-drug HIV regimen hits PhIII targets
read more© 1994 - 2026 B.M. Pharmaceuticals